Summary: Background: Advances in microelectronics have greatly expanded the capabilities and clinical potential of ingestible electronic devices.Aim: To provide an overview of the structure and potential impact of ingestible devices in development that are relevant to the gastrointestinal tract.Methods: We performed a detailed literature search to inform this narrative review.Results: Technical success of ingestible electronic devices relies on the ability to miniaturise the microelectronic circuits, sensors and components for interventional functions while being sufficiently powered to fulfil the intended function. These devices offer the advantages of being convenient and minimally invasive, with real‐time assessment often possible and with minimal interference to normal physiology. Safety has not been a limitation, but defining and controlling device location in the gastrointestinal tract remains challenging. The success of capsule endoscopy has buoyed enthusiasm for the concepts, but few ingestible devices have reached clinical practice to date, partly due to the novelty of the information they provide and also due to the challenges of adding this novel technology to established clinical paradigms. Nonetheless, with ongoing technological advancement and as understanding of their potential impact emerges, acceptance of such technology will grow. These devices have the capacity to provide unique insight into gastrointestinal physiology and pathophysiology. Interventional functions, such as sampling of tissue or luminal contents and delivery of therapies, may further enhance their ability to sharpen gastroenterological diagnoses, monitoring and treatment.Conclusions: The development of miniaturised ingestible microelectronic‐based devices offers exciting prospects for enhancing gastroenterological research and the delivery of personalised, point‐of‐care medicine.
20 July 2022 in Journal of Gastroenterology and Hepatology
Background and Aim: Hypermobile Ehlers–Danlos syndrome (hEDS) and the hypermobility spectrum disorders (HSD) can be challenging to diagnose and manage. Gastrointestinal symptoms and disorders of gut‐brain interaction are common in this cohort and multifactorial in origin. The primary aim of this review is to arm the gastroenterologist with a clinically useful understanding of HSD/hEDS, by exploring the association of gastrointestinal disorders with HSD/hEDS, highlighting current pathophysiological understanding and providing a pragmatic approach to managing these patients.Methods: Literature relevant to the gastrointestinal system and hypermobile Ehlers–Danlos syndrome was systematically searched, critically appraised, and summarized.Results: Diagnosis is based upon clinical criteria and a genetic basis is yet to be defined. The prevalence of many gut symptoms, including abdominal pain (69%vs27%,P < 0.0001), postprandial fullness (34%vs16%,P = 0.01), constipation (73%vs16%,P < 0.001), and diarrhea (47%vs9%,P < 0.001) are significantly higher in HSD/hEDS compared with non‐HSD/hEDS individuals. Disorders of gut‐brain interaction are also common, particularly functional dyspepsia. The pathophysiology of gut symptoms is poorly understood but may involve effects of connective tissue laxity and its functional consequences, and the influence of autonomic dysfunction, medication and comorbid mental health disorders. Awareness is the key to early diagnosis. Management is limited in evidence‐base but ideally should include an integrated multidisciplinary approach.Conclusions: HSD/hEDS is a multisystemic disorder in which gastrointestinal symptoms, particularly related to disorders of gut‐brain interaction are common. Deficiencies in knowledge regarding the pathophysiological processes limit evidence‐based interventions and remain important areas for future research.
9 September 2022 in Alimentary Pharmacology & Therapeutics
Summary: Background: Accurate definition of the gastroduodenal and ileocaecal junctions (GDJ, ICJ) is essential for the measurement of regional transit times.Aims: To compare the assessment of these landmarks using the novel gas‐sensing capsule and validated wireless motility capsule (WMC), and to evaluate intra‐subject variance in transit timesMethods: Healthy subjects ingested the gas‐sensing capsule and WMC tandemly in random order. Inter‐observer agreement was evaluated by intra‐class correlation coefficient (ICC). Agreement between the paired devices' transit times was assessed using Bland–Altman analysis; coefficient of variation was performed to express intra‐individual variance in transit times. Similar analyses were completed with tandemly ingested gas‐sensing capsules.Results: The inter‐observer agreement for landmarks for both capsules was excellent (mean ICC ≥0.97) in 50 studies. The GDJ was identifiable in 92% of the gas‐sensing capsule studies versus 82% of the WMC studies (p = 0.27); the ICJ in 96% versus 84%, respectively (p = 0.11). In the primary cohort (n = 26), median regional transit times differed by less than 6 min between paired capsules. Bland–Altman revealed a bias of −0.12 (95% limits of agreement, −0.94 to 0.70) hours for GDJ and − 0.446 (−2.86 to 2.0) hours for ICJ. Similar results were found in a demographically distinct validation cohort (n = 24). For tandemly ingested gas‐sensing capsules, coefficients of variation of transit times were 11%–35%, which were similar to variance between the paired gas‐sensing capsule and WMC, as were the biases. The capsules were well tolerated.Conclusions: Key anatomical landmarks are accurately identified with the gas‐sensing capsule in healthy individuals. Intra‐individual differences in transit times between capsules are probably due to physiological factors. Studies in populations with gastrointestinal diseases are now required.
30 June 2023 in Alimentary Pharmacology & Therapeutics
Summary: Background: Carbohydrate fermentation plays a pivotal role in maintaining colonic health with excessive proximal and deficient distal fermentation being detrimental.Aims: To utilise telemetric gas‐ and pH‐sensing capsule technologies for defining patterns of regional fermentation following dietary manipulations, alongside conventional techniques of measuring fermentation.Methods: In a double‐blind crossover trial, 20 patients with irritable bowel syndrome were fed low FODMAP diets that included no extra fibre (total fibre content 24 g/day), or additional poorly fermented fibre, alone (33 g/day) or with fermentable fibre (45 g/day) for 2 weeks. Plasma and faecal biochemistry, luminal profiles defined by tandem gas‐ and pH‐sensing capsules, and faecal microbiota were assessed.Results: Plasma short‐chain fatty acid (SCFA) concentrations (μmol/L) were median (IQR) 121 (100–222) with fibre combination compared with 66 (44–120) with poorly fermented fibre alone (p = 0.028) and 74 (55–125) control (p = 0.069), but no differences in faecal content were observed. Luminal hydrogen concentrations (%), but not pH, were higher in distal colon (mean 4.9 [95% CI: 2.2–7.5]) with fibre combination compared with 1.8 (0.8–2.8) with poorly fermented fibre alone (p = 0.003) and 1.9 (0.7–3.1) control (p = 0.003). Relative abundances of saccharolytic fermentative bacteria were generally higher in association with supplementation with the fibre combination.Conclusions: A modest increase in fermentable plus poorly fermented fibres had minor effects on faecal measures of fermentation, despite increases in plasma SCFA and abundance of fermentative bacteria, but the gas‐sensing capsule, not pH‐sensing capsule, detected the anticipated propagation of fermentation distally in the colon. The gas‐sensing capsule technology provides unique insights into localisation of colonic fermentation.Trial registration: ACTRN12619000691145.
5 December 2017 in Alimentary Pharmacology & Therapeutics
Background: Ingestible wireless motility capsules enable locoregional quantification of luminal pH and concentrations of hydrogen and carbon dioxide in the human colon. Aim: To evaluate these measures in the colon of healthy adults. Methods: Gas‐sensing and pH‐sensing wireless motility capsules were ingested tandemly and repeatedly over time. Measurements were analysed and compared in proximal and distal segments of the colon. Results: In paired datasets from 37 participants, colonic pH rose from a median 6.3 (IQR 5.8–6.9) proximally to 7.0 (6.6–7.2) distally ( p < 0.001). Concentrations of carbon dioxide rose in nearly all participants from 12.7 (9.1–18.6) proximally to 18.8 (11.9–28.1) %.h/h distally ( p < 0.001) with a positive correlation between proximal and distal colon ( r = 0.76; p < 0.001). Hydrogen concentrations showed widely varied proximal‐to‐distal gradients with an increase in 69% of participants, but no correlation between proximal and distal colon measures. No significant correlations between colonic pH, hydrogen concentrations, and carbon dioxide concentrations were observed. Comparison of hydrogen and carbon dioxide concentrations between tandem gas‐sensing capsules by Bland–Altman analysis ( n = 24) showed minimal (< 1.2%) bias for both measures, and gas metrics on repeat ingestion were similar ( n = 20). However, there was greater variance in the distal colon. Conclusions: Both wireless motility capsules evaluate different yet complementary aspects of colonic fermentation. Carbon dioxide concentrations that most likely reflect overall microbial metabolic activity were consistently greater distally, while proximal‐to‐distal gradients in hydrogen concentrations varied, likely due to inter‐subject variations in dietary carbohydrate and/or methanogenesis. Luminal pH poorly reflects carbohydrate fermentation in the distal colon. Trial Registration: ACTRN12619001219178 and ACTRN12622000422729